Published in Cancer Res on June 22, 2011
Comparison of peptide-major histocompatibility complex tetramers and dextramers for the identification of antigen-specific T cells. Clin Exp Immunol (2014) 0.97
Antitumor activity of celastrol nanoparticles in a xenograft retinoblastoma tumor model. Int J Nanomedicine (2012) 0.92
Antibody stabilization of peptide-MHC multimers reveals functional T cells bearing extremely low-affinity TCRs. J Immunol (2014) 0.85
DRAM1 regulates apoptosis through increasing protein levels and lysosomal localization of BAX. Cell Death Dis (2015) 0.83
CD8(+) T-cell recognition of a synthetic epitope formed by t-butyl modification. Immunology (2014) 0.75
A genome-wide association study identifies six susceptibility loci for chronic lymphocytic leukemia. Nat Genet (2008) 4.37
Human tumor-derived exosomes selectively impair lymphocyte responses to interleukin-2. Cancer Res (2007) 3.07
Mcl-1 expression has in vitro and in vivo significance in chronic lymphocytic leukemia and is associated with other poor prognostic markers. Blood (2008) 2.88
A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial). J Natl Cancer Inst (2003) 2.68
Cancer exosomes trigger fibroblast to myofibroblast differentiation. Cancer Res (2010) 2.62
Human tumor-derived exosomes down-modulate NKG2D expression. J Immunol (2008) 2.53
Common variants at 2q37.3, 8q24.21, 15q21.3 and 16q24.1 influence chronic lymphocytic leukemia risk. Nat Genet (2010) 2.45
Induction of heat shock proteins in B-cell exosomes. J Cell Sci (2005) 2.21
European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I. Eur Urol (2007) 2.21
The role of surgery in high-risk localised prostate cancer. BJU Int (2011) 2.19
Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials. Lancet Oncol (2009) 2.18
Telomere dysfunction and fusion during the progression of chronic lymphocytic leukemia: evidence for a telomere crisis. Blood (2010) 2.16
Can urinary exosomes act as treatment response markers in prostate cancer? J Transl Med (2009) 2.14
A single autoimmune T cell receptor recognizes more than a million different peptides. J Biol Chem (2011) 2.06
Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial. Lancet Oncol (2012) 2.06
Proteomics analysis of bladder cancer exosomes. Mol Cell Proteomics (2010) 2.04
Radioisotopes for the palliation of metastatic bone cancer: a systematic review. Lancet Oncol (2005) 1.95
CD49d is the strongest flow cytometry-based predictor of overall survival in chronic lymphocytic leukemia. J Clin Oncol (2014) 1.92
Cancer exosomes express CD39 and CD73, which suppress T cells through adenosine production. J Immunol (2011) 1.90
The nature of telomere fusion and a definition of the critical telomere length in human cells. Genes Dev (2007) 1.88
Issues in applying multi-arm multi-stage methodology to a clinical trial in prostate cancer: the MRC STAMPEDE trial. Trials (2009) 1.81
The clinical management of patients with a small volume of prostatic cancer on biopsy: what are the risks of progression? A systematic review and meta-analysis. Cancer (2008) 1.79
Adhesion and signaling by B cell-derived exosomes: the role of integrins. FASEB J (2004) 1.77
Immunological responses in women with human papillomavirus type 16 (HPV-16)-associated anogenital intraepithelial neoplasia induced by heterologous prime-boost HPV-16 oncogene vaccination. Clin Cancer Res (2004) 1.51
Flexible trial design in practice - stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial. Trials (2012) 1.48
Structural basis for the killing of human beta cells by CD8(+) T cells in type 1 diabetes. Nat Immunol (2012) 1.46
Does the extent of carcinoma in prostatic biopsies predict prostate-specific antigen recurrence? A systematic review. Eur Urol (2008) 1.46
Intravesical therapy for superficial bladder cancer: a systematic review of randomised trials and meta-analyses. Cancer Treat Rev (2010) 1.43
Clinical coding for electrophysiology and device procedures: why and how to get it right. Clin Med (2012) 1.40
Antigen-presenting cell exosomes are protected from complement-mediated lysis by expression of CD55 and CD59. Eur J Immunol (2003) 1.40
Levels of expression of endothelial markers specific to tumour-associated endothelial cells and their correlation with prognosis in patients with breast cancer. Clin Exp Metastasis (2004) 1.37
European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II. Eur Urol (2007) 1.37
The prognostic significance of perineural invasion in prostatic cancer biopsies: a systematic review. Cancer (2007) 1.29
Improving the TNM classification: findings from a 10-year continuous literature review. Int J Cancer (2014) 1.27
Effects of the aurora kinase inhibitors AZD1152-HQPA and ZM447439 on growth arrest and polyploidy in acute myeloid leukemia cell lines and primary blasts. Haematologica (2008) 1.25
Expansion of a CD8(+)PD-1(+) replicative senescence phenotype in early stage CLL patients is associated with inverted CD4:CD8 ratios and disease progression. Clin Cancer Res (2011) 1.25
Expression of membrane type-1 matrix metalloproteinase, MT1-MMP in human breast cancer and its impact on invasiveness of breast cancer cells. Int J Mol Med (2006) 1.21
Systemic therapy for advancing or metastatic prostate cancer (STAMPEDE): a multi-arm, multistage randomized controlled trial. BJU Int (2008) 1.19
Interaction with vascular endothelium enhances survival in primary chronic lymphocytic leukemia cells via NF-kappaB activation and de novo gene transcription. Cancer Res (2010) 1.19
Competition between CTL narrows the immune response induced by prime-boost vaccination protocols. J Immunol (2002) 1.18
Genetic and structural basis for selection of a ubiquitous T cell receptor deployed in Epstein-Barr virus infection. PLoS Pathog (2010) 1.18
Targeting matrilysin and its impact on tumor growth in vivo: the potential implications in breast cancer therapy. Clin Cancer Res (2005) 1.15
Peptide length determines the outcome of TCR/peptide-MHCI engagement. Blood (2012) 1.13
Proteomics analysis of cancer exosomes using a novel modified aptamer-based array (SOMAscan™) platform. Mol Cell Proteomics (2014) 1.08
Telomere dysfunction accurately predicts clinical outcome in chronic lymphocytic leukaemia, even in patients with early stage disease. Br J Haematol (2014) 1.07
Tight junctions in cancer metastasis. Front Biosci (Landmark Ed) (2011) 1.07
Abnormal serum free light chain ratios are associated with poor survival and may reflect biological subgroups in patients with chronic lymphocytic leukaemia. Br J Haematol (2008) 1.05
The Hsp90 inhibitor NVP-AUY922-AG inhibits NF-κB signaling, overcomes microenvironmental cytoprotection and is highly synergistic with fludarabine in primary CLL cells. Oncotarget (2012) 1.05
The Kiss-1/Kiss-1R complex as a negative regulator of cell motility and cancer metastasis (Review). Int J Mol Med (2013) 1.04
Chemotherapy for hormone-refractory prostate cancer. Cochrane Database Syst Rev (2006) 1.04
Recovery of CD8+ T-cell function during systemic chemotherapy in advanced ovarian cancer. Cancer Res (2005) 1.03
The novel nuclear factor-kappaB inhibitor LC-1 is equipotent in poor prognostic subsets of chronic lymphocytic leukemia and shows strong synergy with fludarabine. Clin Cancer Res (2008) 1.02
CDKI-71, a novel CDK9 inhibitor, is preferentially cytotoxic to cancer cells compared to flavopiridol. Int J Cancer (2011) 1.02
Expression profile of receptor activator of nuclear-κB (RANK), RANK ligand (RANKL) and osteoprotegerin (OPG) in breast cancer. Anticancer Res (2013) 1.00
A novel Cdk9 inhibitor preferentially targets tumor cells and synergizes with fludarabine. Oncotarget (2014) 0.97
Identification of HLA-DR1- and HLA-DR15-restricted human papillomavirus type 16 (HPV16) and HPV18 E6 epitopes recognized by CD4+ T cells from healthy young women. J Gen Virol (2007) 0.97
Common polymorphism G(-248)A in the promoter region of the bax gene results in significantly shorter survival in patients with chronic lymphocytic Leukemia once treatment is initiated. J Clin Oncol (2005) 0.97
The effect of immunoglobulin VH gene mutation status and other prognostic factors on the incidence of major infections in patients with chronic lymphocytic leukemia. Cancer (2006) 0.97
The prostate transglutaminase (TGase-4, TGaseP) regulates the interaction of prostate cancer and vascular endothelial cells, a potential role for the ROCK pathway. Microvasc Res (2008) 0.96
Defining the prognosis of early stage chronic lymphocytic leukaemia patients. Br J Haematol (2011) 0.96
Flavopiridol induces apoptosis in B-cell chronic lymphocytic leukaemia cells through a p38 and ERK MAP kinase-dependent mechanism. Leuk Lymphoma (2003) 0.95
Beta2-microglobulin is a better predictor of treatment-free survival in patients with chronic lymphocytic leukaemia if adjusted according to glomerular filtration rate. Br J Haematol (2009) 0.95
Rel a is an independent biomarker of clinical outcome in chronic lymphocytic leukemia. J Clin Oncol (2009) 0.95
Anti-CD8 antibodies can trigger CD8+ T cell effector function in the absence of TCR engagement and improve peptide-MHCI tetramer staining. J Immunol (2011) 0.94
Expression of the prostate transglutaminase (TGase-4) in prostate cancer cells and its impact on the invasiveness of prostate cancer. J Exp Ther Oncol (2007) 0.94
Com-1/p8 acts as a putative tumour suppressor in prostate cancer. Int J Mol Med (2006) 0.94
Mimicking the tumour microenvironment: three different co-culture systems induce a similar phenotype but distinct proliferative signals in primary chronic lymphocytic leukaemia cells. Br J Haematol (2012) 0.94
Telomere dysfunction and its role in haematological cancer. Br J Haematol (2012) 0.93
CD49d is an independent prognostic marker that is associated with CXCR4 expression in CLL. Leuk Res (2010) 0.93
Bone morphogenetic protein and bone metastasis, implication and therapeutic potential. Front Biosci (Landmark Ed) (2011) 0.93
Use of B cell-bound HLA-A2 class I monomers to generate high-avidity, allo-restricted CTLs against the leukemia-associated protein Wilms tumor antigen. Blood (2004) 0.93
Type II transmembrane serine protease (TTSP) deregulation in cancer. Front Biosci (Landmark Ed) (2011) 0.93
Activation of CD40 in cervical carcinoma cells facilitates CTL responses and augments chemotherapy-induced apoptosis. J Immunol (2005) 0.92
Does the PGC-1/PPARgamma pathway play a role in Com-1/p8 mediated cell growth inhibition in prostate cancer? Int J Mol Med (2006) 0.92
Elevated levels of tumour endothelial marker-8 in human breast cancer and its clinical significance. Int J Oncol (2006) 0.92
T-cell receptor tetramer binding or the lack there of does not necessitate antigen reactivity in T-cell receptor transduced T cells. Cancer Immunol Immunother (2005) 0.91
Hotspot autoimmune T cell receptor binding underlies pathogen and insulin peptide cross-reactivity. J Clin Invest (2016) 0.90